Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced that Tolefi SA’s shares benefit from a double voting right as of May 3, 2021. As a result, the Company’s total number of voting rights is now 17,373,181.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on 3 May 2021 following the Double Voting Rights:
|Total amount of share capital (EUR)||52,211,200.33|
|Total Number of shares with single voting rights||12,637,131|
|Total Number of shares with double voting rights||2,368,025|
|Total Number of Shares||15,005,156|
|Total of voting rights||17,373,181|
|Total number of attributed warrants||1,802,756|
|Total number of shares with voting rights that could be created following the exercise of the attributed warrants||1,802,756|
|Total number of diluted shares (Outstanding shares + Warrants)||16,807,912|
|Total number of diluted shares with voting rights||19.175.937|
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): email@example.com.
Further questions about the content of this release can be sent to firstname.lastname@example.org.